<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00617240</url>
  </required_header>
  <id_info>
    <org_study_id>05-2992 GCRC-2501</org_study_id>
    <nct_id>NCT00617240</nct_id>
  </id_info>
  <brief_title>Strategies to Reduce Antipsychotic-Associated Weight Gain in Youth</brief_title>
  <acronym>PREVENT</acronym>
  <official_title>Metformin Mitigation of Atypical Antipsychotic-Induced Metabolic Dysregulation in Adolescent Youth</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of North Carolina, Chapel Hill</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Foundation of Hope, North Carolina</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of North Carolina, Chapel Hill</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this pilot study is to determine whether starting metformin in conjunction
      with a second-generation antipsychotic (SGA) and providing information about healthy eating
      and activity will prevent or reduce the amount of weight gain and the metabolic changes in
      adolescent youth typically seen with second-generation antipsychotic medication.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a 24 week, placebo-controlled, random assignment pilot study in which participants
      will be randomized in a 1:1 ratio to receive either flexible-dose treatment with metformin
      for 6 months as well as a newly initiated second generation antipsychotic medication or to
      receive placebo and the newly initiated antipsychotic medication. All subjects will also be
      provided healthy lifestyle instruction. The study involves monthly visits for the duration of
      the study. Participants may be treated as inpatients or outpatients throughout the course of
      the study. Participants will receive a psychiatric evaluation, physical exam, lab work, ECG,
      medication treatment, and psychiatric care.

      The goal is to evaluate the safety and efficacy of means to prevent and treat weight gain and
      the associated endocrine, metabolic, and inflammatory changes caused by antipsychotic
      medications. Behavioral treatments to reduce weight gain and metabolic problems after weight
      gain has occurred have had little impact. Such interventions must be intensive and sustained
      over months, if not years to be effective. Although basic lifestyle instruction (diet and
      physical activity) should be the standard of care for all children and adolescents at risk
      for becoming overweight, pharmacologic interventions may be the best option for substantially
      augmenting behavioral approaches to weight management.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2007</start_date>
  <completion_date type="Actual">October 2012</completion_date>
  <primary_completion_date type="Actual">October 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline to Week 24 in Body Mass Index (BMI)</measure>
    <time_frame>0-24 weeks</time_frame>
    <description>Change in BMI-Body Mass Index (BMI) is a measure of body fat based on height, weight,gender and chronological age. Change in BMI is calculated as 24 weeks BMI minus the baseline BMI.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline to Week 24 in Weight</measure>
    <time_frame>24 weeks</time_frame>
    <description>Change in weight is calculated as 24 weeks weight minus the baseline weight.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline to Week 24 in Fat Mass</measure>
    <time_frame>24 weeks</time_frame>
    <description>Fat mass is a measure of excess body fat. Change in Fat Mass is calculated as 24 weeks fat mass minus the baseline fat mass.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 24 in Insulin Level</measure>
    <time_frame>24 weeks</time_frame>
    <description>Insulin is a peptide hormone and regulates carbohydrate and fat metabolism in the body.Change in Insulin level is calculated as the 24 weeks insulin level minus the baseline insulin level.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 24 in Cholesterol Level</measure>
    <time_frame>24 weeks</time_frame>
    <description>According to the lipid hypothesis, abnormal cholesterol levels are strongly associated with cardiovascular disease because these promote atherosclerosis.Cholesterol levels are measured in milligrams (mg) of cholesterol per deciliter(dL) of blood.Change in cholesterol levels is measured at 24 weeks minus the levels at baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 24 in Triglycerides</measure>
    <time_frame>24 weeks</time_frame>
    <description>In the human body, high levels of triglyceride fats in the bloodstream have been linked to atherosclerosis and, by extension, the risk of heart disease and stroke. A change in triglycerides is calculated from 24 weeks minus baseline levels.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Metabolic Syndrome</measure>
    <time_frame>24 weeks</time_frame>
    <description>Metabolic syndrome is a combination of the medical disorders that, when co-occurring, increase the risk of developing cardiovascular disease and diabetes.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">9</enrollment>
  <condition>Weight Gain</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>metformin in doses from 250mg to 2000mg/day for 26 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matched placebo to metformin, doses between 250/0mg and 2000/0mg per day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>metformin</intervention_name>
    <description>500mg tablets, 250mg to 2000mg/day, po, BID to TID, 26 weeks</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Glucophage</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>500/0mg tablets, 250-2000mg/day divided BID to TID, po, 26 weeks</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects will be between the ages of 10 and 17, male or female, any race or ethnicity

          -  Any SPMI pediatric diagnosis that meets DSM-IV criteria and frequently is treated with
             a SGA- typically but not limited to psychotic, mood, pervasive developmental,
             oppositional defiant, and conduct disorders

          -  SGA-na√Øve or less than 2 weeks exposure to any SGA, except ziprasidone

          -  Legal guardian able and willing to give written informed consent

          -  If competent, subject able and willing to assent for their own participation

        Exclusion Criteria:

          -  Previous trial of metformin

          -  Recommendation for treatment with clozapine or ziprasidone

          -  Current use of insulin or any oral hypoglycemic agent

          -  Current use of a medication known to mitigate weight gain - amantidine, histamine (H2)
             antagonists (cimetidine, ranitidine, nizatidine), topiramate, orlistat, sibutramine,
             stimulants (dextroamphetamine, methylphenidate)

          -  Any current or past diagnosis of an eating disorder

          -  Diabetes mellitus

          -  Current active thyroid (TSH &gt;18 microIU/ml; T4 total &gt;18 mcg/dl), hepatic (2 LFTs &gt;4x
             upper limits of normal), renal (serum Creatinine &gt;1.4 mg/dL in females and serum
             Creatinine &gt;1.5 mg/dL in males), cardiac, gastrointestinal, or adrenal disease

          -  Current substance abuse/dependence within past 2 weeks; a positive urine tox screen at
             baseline in the absence of meeting criteria for abuse/dependence will not preclude
             enrollment.

          -  Pregnancy or breast feeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Linmarie Sikich, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Unversity of North Carolina, Department of Psychiatry</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of North Carolina, Department of Psychiatry</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 5, 2008</study_first_submitted>
  <study_first_submitted_qc>February 14, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 15, 2008</study_first_posted>
  <results_first_submitted>September 2, 2013</results_first_submitted>
  <results_first_submitted_qc>February 7, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 11, 2014</results_first_posted>
  <last_update_submitted>February 7, 2014</last_update_submitted>
  <last_update_submitted_qc>February 7, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 11, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of North Carolina, Chapel Hill</investigator_affiliation>
    <investigator_full_name>Linmarie Sikich, MD</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>antipsychotic</keyword>
  <keyword>metformin</keyword>
  <keyword>children</keyword>
  <keyword>adolescents</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Weight Gain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Antipsychotic Agents</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The first subject was enrolled into the study in January 2007 and enrollment ended in June 2009. All participants came to the ASPIRE clinic for all study visits.</recruitment_details>
      <pre_assignment_details>The study sought to recruit participants who had minimal or no prior exposure to second generation antipsychotics and no previous treatment with metformin.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Metformin</title>
          <description>metformin in doses from 250mg to 2000mg/day for 26 weeks</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Matched placebo to metformin, doses between 250/0mg and 2000/0,g per day</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Metformin</title>
          <description>metformin in doses from 250mg to 2000mg/day for 26 weeks</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Matched placebo to metformin, doses between 250/0mg and 2000/0,g per day</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="5"/>
            <count group_id="B2" value="4"/>
            <count group_id="B3" value="9"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14.20" spread="1.643"/>
                    <measurement group_id="B2" value="14.25" spread="2.754"/>
                    <measurement group_id="B3" value="14.22" spread="2.048"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline to Week 24 in Body Mass Index (BMI)</title>
        <description>Change in BMI-Body Mass Index (BMI) is a measure of body fat based on height, weight,gender and chronological age. Change in BMI is calculated as 24 weeks BMI minus the baseline BMI.</description>
        <time_frame>0-24 weeks</time_frame>
        <population>All participants who took at least one dose of study treatment and had at least one post baseline assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Metformin</title>
            <description>metformin in doses from 250mg to 2000mg/day for 26 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matched placebo to metformin, doses between 250/0mg and 2000/0,g per day</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 24 in Body Mass Index (BMI)</title>
          <description>Change in BMI-Body Mass Index (BMI) is a measure of body fat based on height, weight,gender and chronological age. Change in BMI is calculated as 24 weeks BMI minus the baseline BMI.</description>
          <population>All participants who took at least one dose of study treatment and had at least one post baseline assessment.</population>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.620" spread="1.250"/>
                    <measurement group_id="O2" value="1.800" spread="0.5701"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline to Week 24 in Weight</title>
        <description>Change in weight is calculated as 24 weeks weight minus the baseline weight.</description>
        <time_frame>24 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Metformin</title>
            <description>metformin in doses from 250mg to 2000mg/day for 26 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matched placebo to metformin, doses between 250/0mg and 2000/0,g per day</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 24 in Weight</title>
          <description>Change in weight is calculated as 24 weeks weight minus the baseline weight.</description>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.138" spread="4.346"/>
                    <measurement group_id="O2" value="10.45" spread="5.882"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline to Week 24 in Fat Mass</title>
        <description>Fat mass is a measure of excess body fat. Change in Fat Mass is calculated as 24 weeks fat mass minus the baseline fat mass.</description>
        <time_frame>24 weeks</time_frame>
        <population>Only participants with complete data on fat mass at both baseline and 24 weeks were utilized.</population>
        <group_list>
          <group group_id="O1">
            <title>Metformin</title>
            <description>metformin in doses from 250mg to 2000mg/day for 26 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matched placebo to metformin, doses between 250/0mg and 2000/0,g per day</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 24 in Fat Mass</title>
          <description>Fat mass is a measure of excess body fat. Change in Fat Mass is calculated as 24 weeks fat mass minus the baseline fat mass.</description>
          <population>Only participants with complete data on fat mass at both baseline and 24 weeks were utilized.</population>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.770" spread="1.770"/>
                    <measurement group_id="O2" value="8.225" spread="1.580"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 24 in Insulin Level</title>
        <description>Insulin is a peptide hormone and regulates carbohydrate and fat metabolism in the body.Change in Insulin level is calculated as the 24 weeks insulin level minus the baseline insulin level.</description>
        <time_frame>24 weeks</time_frame>
        <population>Only participants with complete data on insulin levels at both baseline and 24 weeks were utilized.</population>
        <group_list>
          <group group_id="O1">
            <title>Metformin</title>
            <description>metformin in doses from 250mg to 2000mg/day for 26 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matched placebo to metformin, doses between 250/0mg and 2000/0,g per day</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 24 in Insulin Level</title>
          <description>Insulin is a peptide hormone and regulates carbohydrate and fat metabolism in the body.Change in Insulin level is calculated as the 24 weeks insulin level minus the baseline insulin level.</description>
          <population>Only participants with complete data on insulin levels at both baseline and 24 weeks were utilized.</population>
          <units>microIU/ml</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.550" spread="4.250"/>
                    <measurement group_id="O2" value="4.80" spread="2.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 24 in Cholesterol Level</title>
        <description>According to the lipid hypothesis, abnormal cholesterol levels are strongly associated with cardiovascular disease because these promote atherosclerosis.Cholesterol levels are measured in milligrams (mg) of cholesterol per deciliter(dL) of blood.Change in cholesterol levels is measured at 24 weeks minus the levels at baseline.</description>
        <time_frame>24 weeks</time_frame>
        <population>Only participants with complete data on cholesterol levels at both baseline and 24 weeks were utilized.</population>
        <group_list>
          <group group_id="O1">
            <title>Metformin</title>
            <description>metformin in doses from 250mg to 2000mg/day for 26 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matched placebo to metformin, doses between 250/0mg and 2000/0,g per day</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 24 in Cholesterol Level</title>
          <description>According to the lipid hypothesis, abnormal cholesterol levels are strongly associated with cardiovascular disease because these promote atherosclerosis.Cholesterol levels are measured in milligrams (mg) of cholesterol per deciliter(dL) of blood.Change in cholesterol levels is measured at 24 weeks minus the levels at baseline.</description>
          <population>Only participants with complete data on cholesterol levels at both baseline and 24 weeks were utilized.</population>
          <units>mg/dl</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.250" spread="17.07"/>
                    <measurement group_id="O2" value="-31.00" spread="15.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 24 in Triglycerides</title>
        <description>In the human body, high levels of triglyceride fats in the bloodstream have been linked to atherosclerosis and, by extension, the risk of heart disease and stroke. A change in triglycerides is calculated from 24 weeks minus baseline levels.</description>
        <time_frame>24 weeks</time_frame>
        <population>Only participants with complete data on triglyceride levels at both baseline and 24 weeks were utilized.</population>
        <group_list>
          <group group_id="O1">
            <title>Metformin</title>
            <description>metformin in doses from 250mg to 2000mg/day for 26 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matched placebo to metformin, doses between 250/0mg and 2000/0,g per day</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 24 in Triglycerides</title>
          <description>In the human body, high levels of triglyceride fats in the bloodstream have been linked to atherosclerosis and, by extension, the risk of heart disease and stroke. A change in triglycerides is calculated from 24 weeks minus baseline levels.</description>
          <population>Only participants with complete data on triglyceride levels at both baseline and 24 weeks were utilized.</population>
          <units>mg/dl</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.667" spread="6.766"/>
                    <measurement group_id="O2" value="-0.5" spread="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Metabolic Syndrome</title>
        <description>Metabolic syndrome is a combination of the medical disorders that, when co-occurring, increase the risk of developing cardiovascular disease and diabetes.</description>
        <time_frame>24 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Metformin</title>
            <description>metformin in doses from 250mg to 2000mg/day for 26 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matched placebo to metformin, doses between 250/0mg and 2000/0,g per day</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Metabolic Syndrome</title>
          <description>Metabolic syndrome is a combination of the medical disorders that, when co-occurring, increase the risk of developing cardiovascular disease and diabetes.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Metformin</title>
          <description>metformin in doses from 250mg to 2000mg/day for 26 weeks</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Matched placebo to metformin, doses between 250/0mg and 2000/0,g per day</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Glaucoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal discomfort/pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Increased sleep</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Cold/Flu</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Motor Tics</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Motor stereotypies</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Low frustration tolerance</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory/Ear Infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Small number of subjects analyzed and recruited, however, based on preliminary data, a larger, multi-site trial was developed.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Linmarie Sikich, MD</name_or_title>
      <organization>The University of North Carolina at Chapel Hill</organization>
      <phone>(919) 972-7500</phone>
      <email>lsikich@med.unc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

